Patients are searching for this trial right now

This page is already ranking on Google. Activate it to start receiving pre-qualified patient leads directly in your inbox.

14-day free trial · $44/mo after · Cancel anytime · Money-back guarantee

NCT07492134 · Vanderbilt University Medical Center

APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis)

What this study is about

The goal of this clinical trial is to determine whether antibiotics improve recovery from acute uncomplicated diverticulitis (AUD) in racially and ethnically diverse United States clinical practice. The main questions it seeks to answer are: * What is the feasibility for completing a subsequent definitive effectiveness trial of antibiotics vs.

View original scientific description

The goal of this clinical trial is to determine whether antibiotics improve recovery from acute uncomplicated diverticulitis (AUD) in racially and ethnically diverse United States clinical practice. The main questions it seeks to answer are: * What is the feasibility for completing a subsequent definitive efficacy trial of antibiotics vs. placebo to treat AUD? * What are the needs for successful recruitment of racial and ethnic subgroups? * What are the effects of a placebo compared to antibiotics for AUD on a range of key patient-centric efficacy and safety endpoints? * How do such effects differ by race and ethnicity? Researchers will compare a placebo to antibiotics to see if AUD can be treated without using antibiotics.

Interventions

DRUG

Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet

amoxicillin-clavulanate:1 tablet \[875 mg amoxicillin; 125 mg clavulanic acid\] every 8 hours

DRUG

Placebo

A placebo matching the antibiotic arm's treatment regimen will be administered for 10 days

DRUG

Metronidazole

metronidazole: 500 mg every 12 hours

DRUG

Cefuroxime

cefuroxime: 500 mg every 12 hours

Primary outcome measures

Recruitment Rate

Time frame: From enrollment through study completion, an average of 2 years.

Patients recruited per week

Adherence

Time frame: From enrollment through study completion, an average of 2 years

Percent of patients completing the course of antibiotics/placebo

Data completeness

Time frame: From enrollment through study completion, an average of 2 years

Percentage of participants for whom a complete data set was collected

Retention

Time frame: From enrollment through study completion, an average of 2 years

Percentage of patients completing all study activities

Acceptability

Time frame: Collected at 14 days and 6 months

Measured by the Acceptability of Intervention Measure (AIM). Four-question survey with scores ranging from 4 (least acceptable) to 20 (most acceptable).

Cross over

Time frame: From enrollment through study completion, an average of 2 years

Defined as the number of placebo subjects that ended up being treated with antibiotics

Who can participate

This study lists these criteria on ClinicalTrials.gov. A study coordinator reviews eligibility during screening — this page does not determine whether you qualify.

Inclusion criteria

  • Patients presenting to the emergency department with left-sided uncomplicated diverticulitis
  • Radiologic score (moderate diverticulitis per Ambrosetti classification)
  • Access to a smartphone with internet access.

Exclusion criteria

  • Complicated diverticulitis (abscess, free air, peritonitis)- severe diverticulitis by Ambrosetti classification
  • Diverticulitis other than left colon
  • Contraindication to use of study medication (ie advanced renal failure or allergy to all antibiotics used in the study)
  • Concurrent cancer diagnosis
  • Concurrent IBD Diagnosis
  • Any other disease process with life expectancy \< 6 months
  • Concurrent chronic pain diagnosis.
  • Women in pregnancy or breastfeeding
  • Antibiotic treatment for any reason in the last 3 weeks
  • Diagnosis of prior episode of acute diverticulitis in the past 3 months
  • Significant comorbidities: diabetes mellitus with organic involvement (retinopathy, angiopathy, nephropathy), emergency assistance for a cardiogenic event in the last 3 months (acute myocardial infarction, angina, heart failure), decompensation of chronic liver disease in the last 3 months (Child ≥ B) and end-stage renal disease.
  • Immunodepression: the absence, and immunodepression is the presence, of any of the following: active neoplastic disease, hematologic malignancy, human immunodeficiency virus long-term corticosteroid treatment, immunosuppressant therapy (20mg pred (or equivalent) for \>2 weeks), transplant, splenectomy and genetic immunodeficiency
  • Previous colectomy
  • Patients with dementia, memory disorders or other cognitive impairment that would impact their ability to provide informed consent or otherwise participate in the trial

Where

  • Nashville, Tennessee

Collaborators

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Related conditions & keywords

Acute Uncomplicated DiverticulitisAntibiotic stewardshipAntimicrobial resistance

Frequently asked questions

What is a clinical trial?

A clinical trial is a research study that tests new medical treatments, drugs, devices, or procedures to determine their safety and effectiveness. Trials are carefully designed and monitored to protect participants while advancing medical knowledge.

Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. Trials must be reviewed and approved, and participants are closely monitored by medical professionals throughout the study. You can withdraw at any time if you choose.

Will I be compensated?

Many clinical trials offer compensation for your time, travel expenses, and inconvenience. The specific compensation varies by study and will be discussed during the screening process. All study-related medical care is typically provided at no cost to participants.

Will I receive a placebo instead of treatment?

When effective treatment exists, participants typically receive either the standard treatment plus the study intervention, or the standard treatment plus placebo. You would not be denied effective care. Placebos are primarily used when no proven treatment is available, or in addition to standard care. Your trial consent form will clearly explain what treatments you may receive.

Can I leave a trial if I change my mind?

Absolutely. Participation in clinical trials is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled.

How long does a clinical trial last?

Trial duration varies widely depending on the study design and purpose. Some trials last just a few weeks, while others may continue for months or years. The study coordinator will provide specific timeline information during your screening call.

Data: ClinicalTrials.gov · synced Jul 8, 2026 · Source of record for eligibility and locations

📊
1 of 100 participants interested
1% interest

See if this study fits

A short prescreen based on this study's listed criteria. A coordinator confirms eligibility — this is not a medical assessment.

Preparing your pre-screening questions…

Study locations

Choose your preferred location, or select flexible during enrollment.

RECRUITING

Nashville

Tennessee

Location available

Express your interest

Share your contact details and a study coordinator can follow up about screening.

Secure & Confidential

Your information is protected and will only be shared with the research team.

What participation can include

  • Study-related care provided by the research team
  • Close monitoring by medical professionals
  • Possible compensation for time and travel*
  • The option to withdraw at any time
  • Contributing to medical research that may help future patients

*Compensation varies by study. Confirm details with coordinator.

Typical next steps

  1. 1.Submit this form
  2. 2.Phone screening
  3. 3.In-person assessment if eligible
  4. 4.Begin participation

Find More Erectile Dysfunction Trials by City

Browse all erectile dysfunction clinical trials in these cities — not just this study.

Looking for Acute Uncomplicated Diverticulitis Treatment in Nashville?

Join others in Tennessee exploring innovative treatment options through clinical research

Acute Uncomplicated Diverticulitis Treatment Options in Nashville, Tennessee

If you're searching for Acute Uncomplicated Diverticulitis treatment in Nashville, participating in a clinical research study may provide access to innovative approaches under expert medical supervision. This study is actively recruiting participants in Nashville and surrounding areas.

Clinical trials offer participants the opportunity to receive cutting-edge treatments while contributing to medical research that may help future patients with Acute Uncomplicated Diverticulitis. All study-related care is provided at no cost to participants.

Local Sites
1 locations in Tennessee
Now Enrolling
Up to 100 participants
Quick Start
Screening available now

Why Consider a Clinical Trial for Acute Uncomplicated Diverticulitis?

Potential Benefits

  • Access to new treatment approaches before public availability
  • Close monitoring by experienced medical professionals
  • Study-related care provided at no cost
  • Contribute to medical research for Acute Uncomplicated Diverticulitis

What to Expect

  • Initial screening to determine eligibility
  • Regular check-ups and monitoring visits
  • Possible compensation for time and travel
  • You can withdraw at any time

Frequently Asked Questions About This Acute Uncomplicated Diverticulitis Study

Important Clinical Trial Information

This information is provided for educational purposes and does not constitute medical advice. Clinical trial participation involves potential risks and benefits. Eligibility requirements apply and will be assessed during the screening process.

Study identifier: NCT07492134. For complete study details, visit ClinicalTrials.gov. Always consult with your healthcare provider before making decisions about your medical care or participating in clinical research.